6926-09-6

Basic information

• Product Name: Boc-Glycine hydrazide
• Synonyms: N-TERT-BUTOXYCARBONYLGLYCYLHYDRAZIDE;BOC-GLYCINE HYDRAZIDE;BUTTPARK 77\04-08;Butoxycarbonylglycine hydrazide;Boc-Glycinehydrazide，98%;Hydrazinocarbonylmethyl-carbamic acid tert-butyl ester;2-Aminoacetohydrazide, 2-BOC protected;tert-Butyl (2-hydrazino-2-oxoethyl)carbamate, 2-[(tert-Butoxycarbonyl)amino]acetohydrazide
• CAS NO: 6926-09-6
• Molecular Formula: C₇H₁₅N₃O₃
• Molecular Weight: 189.21
• Mol File: 6926-09-6.mol
• Article Data: 26

Chemical Properties

• Melting Point: 111-115
• Boiling Point: 386.5oC at 760 mmHg
• Flash Point: 187.5oC
• Appearance: /
• Density: 1.139g/cm3
• Vapor Pressure: 3.54E-06mmHg at 25°C
• Refractive Index: 1.477
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 11.40±0.46(Predicted)
• CAS DataBase Reference: Boc-Glycine hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-Glycine hydrazide(6926-09-6)
• EPA Substance Registry System: Boc-Glycine hydrazide(6926-09-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 6926-09-6(Hazardous Substances Data)

Usage

Uses

Boc-Glycine hydrazide is used as organic synthesis intermediate and pharmaceutical intermediate, mainly used in laboratory research and development process and chemical production process.

Synthesis

N-Protected Hydrazides 2a-l; General Procedure The protected amino acid 1 (2 equiv) and EDAC (2 equiv) were dissolved in the minimum amount of CH2Cl2 at 0 °C. The mixture was stirred at 0 °C for 2 h. PhthNNH2 (1 equiv) was added and the mixture was stirred at 0 °C for 1 h and then at r.t. overnight. Distillation of the solvent under reduced pressure gave a product which was dissolved in EtOAc and washed successively with 1 M KHSO4, sat. aq NaHCO3, and brine. The organic layer was then dried (Na2SO4), filtered, and concentrated in vacuo. The residue was precipitated with Et2O to yield compound 2. If necessary, the residue was purified by column chromatography (silica gel, hexane- EtOAc, 3:7 to 7:3). Compounds 4a-l; General Procedure Aminomethylated polystyrene resin (3 equiv; 1.1 mmol/g, 100-200 mesh) was conditioned for 10 min at r.t. in CH2Cl2. Then 2 (1 equiv) was added, and the mixture was slowly stirred for 24 h at r.t. The mixture was filtered and the solvent was evaporated in vacuo to give product 4. Compound 4h, yield 89%.

InChI:InChI=1/C7H15N3O3/c1-7(2,3)13-6(12)9-4-5(11)10-8/h4,8H2,1-3H3,(H,9,12)(H,10,11)

Upstream product

• 31954-27-5 N-(tert-butoxycarbonyl)glycine methyl ester 
• 83316-95-4 2-oxo-2-phenylethyl 2-(tert-butoxycarbonylamino)acetate 

Downstream Products

• 877678-80-3 tert-butyl {[4-[2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-chlorophenyl]-5-(4-phenylpiperidin-1-yl)-4H-1,2,'4-triazol-3-yl]methyl}carbamate 
• 877678-81-4 tert-butyl {[4-[4-chloro-2-(hydroxymethyl)phenyl]-5-(4-phenylpiperidin-1-yl)-4H-1,2,4-triazol-3-yl]methyl}carbamate 
• 1092361-50-6 C₂₈H₃₅F₂N₅O₃ 
• 1188405-97-1 C₂₇H₃₆N₆O₆ 
• 716329-43-0 tert-butyl ((1,3,4-oxadiazol-2-yl)methyl)carbamate 

Relevant articles and documents

Targeting RECQL5 Functions, by a Small Molecule, Selectively Kills Breast Cancer in Vitro and in Vivo

Clinical and preclinical data reveal that RECQL5 protein overexpression in breast cancer was strongly correlated with poor prognosis, survival, and therapeutic resistance. In the current investigation, we report design, synthesis, and specificity of a small molecule, 4a, which can preferentially kill RECQL5-expressing breast cancers but not RECQL5 knockout. Our stringent analysis showed that compound 4a specifically sensitizes RECQL5-expressing cancers, while it did not have any effect on other members of DNA RECQL-helicases. Integrated approaches of organic synthesis, biochemical, in silico molecular simulation, knockouts, functional mutation, and rescue experiments showed that 4a potently inhibits RECQL5-helicase activity and stabilizes RECQL5-RAD51 physical interaction, leading to impaired HRR and preferential killing of RECQL5-expressing breast cancer. Moreover, 4a treatment led to the efficient sensitization of cisplatin-resistant breast cancers but not normal mammary epithelial cells. Pharmacologically, compound 4a was orally effective in reducing the growth of RECQL5-expressing breast tumors (human xenograft) in NUDE-mice with no appreciable toxicity to the vital organs.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.